Username:
Password:
Forgot Password?
Remember me
Decade: 2010-2010 2000-2009 1990-1999
Year: 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000
Issues: Vol. 38 December, 2002 p.S1-S31-Supplement 8 Vol. 38 No. 18 December, 2002 p.I-XII Vol. 38 November, 2002 p.S3-S188-Supplement 7 Vol. 38 No. 17 November, 2002 p.I-X Vol. 38 No. 16 November, 2002 p.I-II Vol. 38 No. 15 October, 2002 p.I-XVIII Vol. 38 September, 2002 p.EX1-EX14-Supplement 6 Vol. 38 September, 2002 p.S1-S87-Supplement 5 Vol. 38 No. 14 September, 2002 p.I-IV Vol. 38 No. 13 September, 2002 p.I-X Vol. 38 No. 12 August, 2002 p.I-IV Vol. 38 No. 11 July, 2002 p.I-IV Vol. 38 No. 10 July, 2002 p.I-IV Vol. 38 No. 9 June, 2002 p.I-VI Vol. 38 No. 8 May, 2002 p.I-VI Vol. 38 No. 7 May, 2002 p.I-VIII Vol. 38 March, 2002 p.I-II-Supplement 4 Vol. 38 March, 2002 p.S2-S179-Supplement 3 Vol. 38 No. 5 March, 2002 p.I-XIV Vol. 38 No. 4 March, 2002 p.I-XX Vol. 38 February, 2002 p.I-II-Supplement 2 Vol. 38 February, 2002 p.S3-S56-Supplement 1 Vol. 38 No. 6 p.I-X Vol. 38 No. 3 p.I-XIV Vol. 38 No. 2 p.I-XVI Vol. 38 No. 1 January, 2002 p.I-XVI
Search Within This Issue
5 Articles:
Abstract: Capecitabine is a fluoropyrimidine carbamate that was rationally designed as an oral drug capable of mimicking continuous infusion 5-fluorouracil (5-FU) and delivering 5-FU preferentially to...
Abstract: The oral, tumour-selective fluoropyrimidine capecitabine represents a major new strategy for the treatment of colorectal cancer. Pooled results from two large, multicentre, open-label, phase...
Abstract: Results from two phase II studies in metastatic breast cancer have shown that the novel, tumour-selective fluoropyrimidine capecitabine provides an effective and well tolerated therapy in pa...
Abstract: The oral fluoropyrimidine, capecitabine is attracting great interest in the context of tumour-selective therapy and rationally designed combination regimens. Agents such as taxanes upregulat...
Breast and colorectal cancer are two of the most common cancers in Europe and the cause of considerable morbidity and mortality. Over the past 20 years, the 5-year survival for patients with both tumo...
